P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease

International Journal of Laboratory Hematology

Volumn 34, Issue 5, 2012, Pages 473-483

  Timur, A A ^a   Murugesan, G ^a   Zhang, L ^a   Aung, P P ^a   Barnard, J ^a   Wang, Q K ^a   Gaussem, P ^b   Silverstein, R L ^a,d   Bhatt, D L ^c   Kottke Marchant, K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b INSERM   (France)

^c HARVARD MEDICAL SCHOOL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Aspirin; Coronary artery disease; P2RY1 and P2RY12 receptors; Platelet reactivity; SNP

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR P2RY1; G PROTEIN COUPLED RECEPTOR P2RY12; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2Y1; RECEPTORS, PURINERGIC P2Y12;

EID: 84865552528     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01420.x     Document Type: Article

References (34)

1. Patrono C. & Rocca B. (2008) Aspirin: promise and resistance in the new millennium. Arteriosclerosis, Thrombosis, and Vascular Biology 28, 25-32.
2. Antithrombotic Trialists' Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860.
3. Berger J.S., Brown D.L. & Becker R.C. (2008) Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. American Journal of Medicine 121, 43-49.
4. Gasparyan A.Y., Watson T. & Lip G.Y. (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. Journal of the American College of Cardiology 51, 1829-1843.
5. Krasopoulos G., Brister S.J., Beattie W.S. & Buchanan M.R. (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. British Medical Journal 336, 195-198.
6. Cattaneo M. (2007) Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. Journal of Thrombosis and Haemostasis 5(Suppl 1), 230-237.
7. Cohen M. (2009) Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheterization and Cardiovascular Interventions 74, 579-597.
8. Goodman T., Ferro A. & Sharma P. (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. British Journal of Clinical Pharmacology 66, 222-232.
9. Rozalski M., Boncler M., Luzak B. & Watala C. (2005) Genetic factors underlying differential blood platelet sensitivity to inhibitors. Pharmacological Reports 57, 1-13.
10. Smyth S.S., Woulfe D.S., Weitz J.I., Gachet C., Conley P.B., Goodman S.G., Roe M.T., Kuliopulos A., Moliterno D.J., French P.A., Steinhubl S.R. & Becker R.C. (2009) G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 29, 449-457.
11. Volonte C. & D'Ambrosi N. (2009) Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS Journal 276, 318-329.
12. Ayyanathan K., Naylor S.L. & Kunapuli S.P. (1996) Structural characterization and fine chromosomal mapping of the human P2Y1 purinergic receptor gene (P2RY1). Somatic Cell and Molecular Genetics 22, 419-424.
13. Leon C., Vial C., Cazenave J.P. & Gachet C. (1996) Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene 171, 295-297.
14. Hetherington S.L., Singh R.K., Lodwick D., Thompson J.R., Goodall A.H. & Samani N.J. (2005) Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arteriosclerosis, Thrombosis, and Vascular Biology 25, 252-257.
15. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., Yang R.B., Nurden P., Julius D. & Conley P.B. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202-207.
16. Fontana P., Dupont A., Gandrille S., Bachelot-Loza C., Reny J.L., Aiach M. & Gaussem P. (2003a) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108, 989-995.
17. Fontana P., Gaussem P., Aiach M., Fiessinger J.N., Emmerich J. & Reny J.L. (2003b) P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 108, 2971-2973.
18. Steinhubl S.R., Berger P.B., Mann J.T. IIII, Fry E.T., DeLago A., Wilmer C. & Topol E.J. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. Journal of American Medical Association 288, 2411-2420.
19. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G. & Fox K.K. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine 345, 494-502.
20. Jefferson B.K., Foster J.H., McCarthy J.J., Ginsburg G., Parker A., Kottke-Marchant K. & Topol E.J. (2005) Aspirin resistance and a single gene. American Journal of Cardiololgy 95, 805-808.
21. 12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. Journal of Thrombosis and Haemostasis 9, 552-561.
22. Hayward C.P.M., Moffat K.A., Raby A., Israels S., Plumhoff E., Flynn G. & Zehnder J.L. (2010) Development of North American consensus guidelines for medical laboratories that perform and interpret platelet function testing using light transmission aggregometry. American Journal of Clinical Pathology 134, 955-963.
23. Censarek P., Freidel K., Udelhoven M., Ku S.J., Hohlfeld T., Meyer-Kirchrath J., Schrör K. & Weber A.A. (2004) Cyclooxygenase COX-2a, a novel COX-2 mRNA variant, in platelets from patients after coronary artery bypass grafting. Thrombosis and Haemostasis 92, 925-928.
24. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K. & Topol E.J. (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. American Journal of Cardiology 88, 230-235.
25. Gum P.A., Kottke-Marchant K., Welsh P.A., White J. & Topol E.J. (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Journal of the American College of Cardiology 41, 961-965.
26. Keating B.J., Tischfield S., Murray S.S., Bhangale T., Price T.S., Glessner J.T., Galver L., Barrett J.C., Grant S.F.A., Farlow D.N., Chandrupatla H.R., Hansen M., Ajmal S., Papanicolaou G.J., Guo Y., Li M., DerOhannessian S., de Bakker P.I.W., Bailey S.D., Montpetit A., Edmondson A.C., Taylor K., Gai X., Wang S.S., Fornage M., Shaikh T., Groop L., Boehnke M., Hall A.S., Hattersley A.T., Frackelton E., Patterson N., Chiang C.W.K., Kim C.E., Fabsitz R.R., Ouwehand W., Price A.L., Munroe P., Caulfield M., Drake T., Boerwinkle E., Reich D., Whitehead A.S., Cappola T.P., Samani N.J., Lusis A.J., Schadt E., Wilson J.G., Koenig W., McCarthy M.I., Kathiresan S., Gabriel S.B., Hakonarson H., Anand S.S., Reilly M., Engert J.C., Nickerson D.A., Rader D.J., Hirschhorn J.N. & FitzGerald G.A. (2008) Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 3, e3583.
27. Murugesan G., Aboudola S., Szpurka H., Verbic M.A., Maciejewski J.P., Tubbs R.R. & Hsi E.D. (2006) Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. American Journal of Clinical Pathology 125, 625-633.
28. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A. & Reich D. (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nature Genetics 38, 904-909.
29. Cattaneo M. (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thrombosis, and Vascular Biology 24, 1980-1987.
30. Lordkipanidze M., Pharand C., Schampaert E., Turgeon J., Palisaitis D.A. & Diodati J.G. (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. European Heart Journal 28, 1702-1708.
31. Rudez G., Pons D., Leebeek F., Monraats P., Schrevel M., Zwinderman A., de Winter R., Tio R., Doevendans P., Jukema W. & de Maat M. (2008) Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Human Mutation 29, 375-380.
32. Lordkipanidze M., Diodati J.G., Palisaitis D.A., Schampaert E., Turgeon J. & Pharand C. (2011) Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thrombosis Research 128, 47-53.
33. Fabre A.C., Malaval C., Ben Addi A., Verdier C., Pons V., Serhan N., Lichtenstein L., Combes G., Huby T., Briand F., Collet X., Nijstad N., Tietge U.J., Robaye B., Perret B., Boeynaems J.M. & Martinez L.O. (2010) P2Y13 receptor is critical for reverse cholesterol transport. Hepatology 52, 1477-1483.
34. Jacquet S., Malaval C., Martinez L.O., Sak K., Rolland C., Perez C., Nauze M., Champagne E., Tercé F., Gachet C., Perret B., Collet X., Boeynaems J.M. & Barbaras R. (2005) The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cellular and Molecular Life Sciences 62, 2508-2515.